Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 294-705-2 | CAS number: 91745-35-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Modern GLP study conducted in accordance with modern guidelines
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
- Report date:
- 2008
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- (Serum chemistry did not include measurement of bile acids. The justification for the choice of vehicle was not included in the study report).
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Amines, bis(hydrogenated tallow alkyl), 2-[[bis(hydrogenated tallow alkyl)amino]carbonyl]benzoates
- EC Number:
- 294-705-2
- EC Name:
- Amines, bis(hydrogenated tallow alkyl), 2-[[bis(hydrogenated tallow alkyl)amino]carbonyl]benzoates
- Cas Number:
- 91745-35-6
- Molecular formula:
- C72H140N2O3-C80H156N2O3
- IUPAC Name:
- Amines, bis(hydrogenated tallow alkyl), 2-[[bis(hydrogenated tallow alkyl)amino]carbonyl]benzoates
- Details on test material:
- - Physical state: Solid
- Analytical purity: >99%.
- Lot/batch No.: E0011-039E
- Expiration date of the lot/batch: 30 October 2012
- Storage condition of test material: Room temperature in the dark.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Raleigh, North Carolina
- Age at study initiation: 7 weeks old
- Weight at study initiation: At initiation of dosing, males weighed 217–267 g and females weighed 148–190 g.
- Fasting period before study: None.
- Housing: Animals were individually housed in clean, stainless steel, wire-mesh cages suspended above cage-board.
- Diet (e.g. ad libitum): Ad libitum, except during functional observational battery and motor activity testing and during the period of fasting prior to blood collection for clinical pathology and scheduled necropsies.
- Water (e.g. ad libitum): Ad libitum.
- Acclimation period: 15 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): Mean daily temperatures ranged from 20.8–22.0 deg C.
- Humidity (%): Mean daily humidity ranged from 32.6–43.9%.
- Air changes (per hr): At least 10
- Photoperiod (hrs dark / hrs light): 12 hours light / 12 hours dark.
IN-LIFE DATES: From: 19 March 2008 To: 30 April 2008
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The appropriate amount of test material for each formulation was weighed into a tared mortar and ground to a fine powder with a pestle. The appropriate amount of ground test material was then weighed into a tared, calibrated storage container. Vehicle was then added to each container to bring the formulations to the calibration mark. Each formulation was homogenised using an electronic homogeniser for approximately five minutes until a uniform mixture was obtained.
The test material formulations were prepared approximately weekly as single formulations for each dosage level., divided into aliquots for daily dispensation and stored at room temperature, protected from light with the following exception. The 100 mg/ml formulation for the last week of dosing (Week 3) was prepared daily on the day of dosing. Daily aliqupts were homogenised for approximately five minutes prior to dosing. The test material formulations were stirred continuously throughout the preparation, sampling and dose administration procedures.
VEHICLE
- Justification for use and choice of vehicle (if other than water): Justification not explicitly provided in study report; however, corn oil is a very common/standard solvent vehicle for test materials that are insoluble in water.
- Concentration in vehicle: 10, 30 and 100 mg/ml
- Amount of vehicle (if gavage): 10 ml/kg.
- Lot/batch no. (if required): 126K0117 and 117K0127
- Purity: Not stated. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Two sets of duplicate samples (1 ml each) for pre-initiation homogeneity determination were collected from the top, middle and bottom strata of formulations prepared at test material concentrations of 5 and 100 mg/ml. The formulations that remained after sampling were divided into aliquots representative of the volumes used for daily dispensation. Representative aliquots were stored at room temperature for 8 and 18 days and samples were collected from the top and bottom strata and analyzed to assess re-suspension homogeneity and stability. One set of samples was analyzed and the other was stored at approximately -20°C as reserve samples to be discarded upon the study director’s approval of the results.
In addition, two sets of duplicate samples (1 ml each) for concentration analyses were
collected for study Weeks 0 and 3 (first daily 100 mg/ml formulation) from the middle stratum of each dosing formulation (including the vehicle formulation administered to the control group). Two sets of duplicate samples (1 ml each) for concentration analyses were also collected from the middle stratum of the second daily 100 mg/ml formulation. One set of samples was analyzed and the other set was stored at approximately -20°C as reserve samples to be discarded upon study director approval of analytical results. All analyses were conducted by the Analytical Chemistry Department, WIL Research Laboratories, LLC using a validated method. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
100, 300 and 1000 mg/kg/day
Basis:
other: Nominal gavaged dose
- No. of animals per sex per dose:
- Group 1, Control group (0 mg/kg/day) 10 animals per sex
Group 2, Low-dose group (100 mg/kg/day) 5 animals per sex
Group 3, Mid-dose group (300 mg/kg/day) 5 animals per sex
Group 4, High-dose group (1000 mg/kg/day) 10 animals per sex - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were selected based on the results of a previous 14-day oral range-finding study.
- Rationale for selecting satellite groups: To investigate the persistence, delayed occurrence and reversibility of potential test substance-related effects.
- Post-exposure recovery period in satellite groups: 14 days
- Section schedule rationale (if not random): Not specified. - Positive control:
- No.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: All animals were observed twice daily, once in the morning and once in the afternoon, for mortality and moribundity.
- Cage side observations checked in table [No.?] were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Clinical examinations were performed twice daily: at the time of dose administration and approximately one to two hours following dose administration.
BODY WEIGHT: Yes
- Time schedule for examinations: Individual body weights were recorded at least weekly.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No. Food consumption for each animal was determined and mean daily diet consumption calculated as g food/animal/day was calculated.
FOOD EFFICIENCY: No.
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION: No.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Blood was sampled for haematology on the day of the scheduled necropsies (Weeks 4 and 6).
- Anaesthetic used for blood collection: Yes (isoflurane).
- Animals fasted: Yes
- How many animals: All animals.
- Parameters in List 1 were examined.
BLOOD COAGULATION: Yes
- Time schedule for collection of blood: Blood was collected for coagulation parameters at the time of euthanasia.
- Animals fasted: Yes
- How many animals: All animals.
- Parameters in List 1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Blood was sampled for clinical chemistry on the day of the scheduled necropsies (Weeks 4 and 6).
- Animals fasted: Yes
- How many animals: All animals.
- Parameters in List 2 were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: Urine was collected overnight prior to the day of scheduled necropsy.
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes.
- Parameters in List 3 were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Functional Observational Battery (FOB) assessments were recorded prior to initiation of dosing and prior to dosing during study Week 3 (final week of dosing period).
- Dose groups that were examined: All animals.
- Battery of functions tested: Parameters in List 4 were assessed.
OTHER:
LOCOMOTOR ACTIVITY: Yes. Locomotor activity was assessed for all animals prior to the initiation of dosing and prior to dosing following functional observationsl battery assessment during study Week 3 (final week of the dosing period).
Locomotor activity was measured automatically using a computerised system linked to a series of infrared photobeams surrounding a clear, plastic rectangular cage. Data were collected in 5-minute epochs and the test session duration was 60 minutes. These data were compiled as six 10-minute subsessions. Data for ambulatory and total locomotor activity (e.g. including grooming) were reported. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table)
HISTOPATHOLOGY: Yes (see table) - Statistics:
- Body weight, body weight change, food consumption, continuous functional observational battery (FOB), clinical pathology and organ weight data were subjected to a parametric one-way analysis of variance (ANOVA) to determine intergroup differences. If ANOVA revealed statistically significant (p<0.05) intergroup variance, Dunnett's test was used to compare the test substance-treated groups to the control group. Functional observational battery parameters that yielded scalar or descriptive data were analyzed using Fisher’s Exact Test.
RANOVA statistical analyses were conducted for locomotor activity counts.
Analyses were conducted using two-tailed tests (except as noted otherwise) for minimum significance levels of 1% and 5%, comparing each test substance-treated group to the control group by sex. Each mean was presented with the standard deviation (S.D.), standard error (S.E.) and the number of animals (N) used to calculate the mean. In addition, percent difference from the control group was calculated for body weights, clinical pathology parameters (excluding urinalysis) and organ weights.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No effects of the test material on the animals were observed at any dose
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No effects of the test material on the animals were observed at any dose
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Oral (gavage) administration of the substance to rats for 28 consecutive days did not result in toxicity in any of the evaluated parameters at dosage levels of 100, 300 and 1000 mg/kg/day. Therefore, the no-observed effect level (NOEL) and the no-observed adverse effect level (NOAEL) for this study is 1000 mg/kg/day, the highest dose tested.
- Executive summary:
The test substance was studied for oral toxicity potential in a 28-day gavage study in Crl:CD(SD) rats. The study was performed to GLP and in accordance with OECD Test Guideline 407. Dosage levels were 0, 100, 300 and 1000 mg/kg/day. The low- and mid-dose groups comprised five male and five female rats each, while the control and high-dose groups each comprised 10 animals of each sex. Following the 28 days of dosing, five animals per sex per group were euthanised; the remaining five animals per sex from the control and high-dose groups were maintained for a 14-day recovery period before sacrifice. Parameters evaluated included mortality, clinical observations, body weight, food consumption, locomotor activity, functional observational battery of assessments for neurotoxicity, haematology, serum chemistry, urinalysis, organ weights, gross pathology and histopathology. No test substance-related adverse effects on any of the evaluated parameters were reported. The no-observed effect level (NOEL) and no-observed adverse effect level (NOAEL) for this study is 1000 mg/kg/day, the highest dose tested.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.